These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 16224442)

  • 1. New developments in adjuvant therapy for breast cancer.
    Sledge GW
    Clin Adv Hematol Oncol; 2005 Sep; 3(9):688-90. PubMed ID: 16224442
    [No Abstract]   [Full Text] [Related]  

  • 2. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31.
    Tan-Chiu E; Yothers G; Romond E; Geyer CE; Ewer M; Keefe D; Shannon RP; Swain SM; Brown A; Fehrenbacher L; Vogel VG; Seay TE; Rastogi P; Mamounas EP; Wolmark N; Bryant J
    J Clin Oncol; 2005 Nov; 23(31):7811-9. PubMed ID: 16258083
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trastuzumab combined with paclitaxel after doxorubicin and cyclophosphamide for operable HER2-positive breast cancer.
    Ferretti G; Felici A; Papaldo P; Carlini P; Fabi A; Cognetti F
    Oncologist; 2006 May; 11(5):533; author reply 534. PubMed ID: 16720857
    [No Abstract]   [Full Text] [Related]  

  • 4. [Adjuvant chemotherapy for breast cancer and targeted therapies].
    Dufresne A; Bachelot T; Blay JY
    Rev Prat; 2008 Mar; 58(5):477-8. PubMed ID: 18524101
    [No Abstract]   [Full Text] [Related]  

  • 5. [Diagnosis and treatment of HER-2-positive breast cancer: Expert consensus of the Chinese Anti-Cancer Association].
    Jiang ZF; Shao ZM; Xu BH
    Zhonghua Zhong Liu Za Zhi; 2010 Feb; 32(2):158-60. PubMed ID: 20403251
    [No Abstract]   [Full Text] [Related]  

  • 6. Why adjuvant trastuzumab led to better outcomes in women with high-risk HER-2-positive breast cancer.
    Altundag K; Baptista MZ
    Breast J; 2006; 12(5):497-8. PubMed ID: 16958977
    [No Abstract]   [Full Text] [Related]  

  • 7. Response and cardiac toxicity of trastuzumab given in conjunction with weekly paclitaxel after doxorubicin/cyclophosphamide.
    Kelly H; Kimmick G; Dees EC; Collichio F; Gatti L; Sawyer L; Ivanova A; Dressler L; Graham ML; Carey LA
    Clin Breast Cancer; 2006 Aug; 7(3):237-43. PubMed ID: 16942640
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinicopathological evaluation of preoperative chemotherapy with doxorubicin plus cyclophosphamide followed by paclitaxel for locally advanced breast cancer].
    Miyake T; Miyahara S; Fujii K; Taniguchi M; Yamamura K; Tadokoro K; Tanimura M; Nakamura H
    Gan To Kagaku Ryoho; 2009 Mar; 36(3):401-5. PubMed ID: 19295263
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant treatment for HER2-positive breast cancer.
    Burki TK
    Lancet Oncol; 2015 Feb; 16(2):e59. PubMed ID: 25601343
    [No Abstract]   [Full Text] [Related]  

  • 10. The safety of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab in HER-2/neu overexpressed/amplified breast cancer.
    Dang C; Fornier M; Sugarman S; Troso-Sandoval T; Lake D; D'Andrea G; Seidman A; Sklarin N; Dickler M; Currie V; Gilewski T; Moynahan ME; Drullinsky P; Robson M; Wasserheit-Leiblich C; Mills N; Steingart R; Panageas K; Norton L; Hudis C
    J Clin Oncol; 2008 Mar; 26(8):1216-22. PubMed ID: 18323546
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Advances in herceptin neoadjuvant therapy and adjuvant therapy of breast cancer].
    Wang LP; Shen KW; Shen ZZ
    Zhonghua Zhong Liu Za Zhi; 2006 Apr; 28(4):241-3. PubMed ID: 16875618
    [No Abstract]   [Full Text] [Related]  

  • 12. Herceptin (trastuzumab): adjuvant and neoadjuvant trials.
    Yaal-Hahoshen N; Safra T
    Isr Med Assoc J; 2006 Jun; 8(6):416-21. PubMed ID: 16833172
    [No Abstract]   [Full Text] [Related]  

  • 13. [Breast cancer: adjuvant therapy with trastuzumab: herceptin adjuvant (HERA) Trial Study, B-31- and N9831-Study].
    Mallmann P
    Internist (Berl); 2006 Nov; 47(11):1183-5. PubMed ID: 17048017
    [No Abstract]   [Full Text] [Related]  

  • 14. A pilot study of adjuvant nanoparticle albumin-bound (nab) paclitaxel and cyclophosphamide, with trastuzumab in HER2-positive patients, in the treatment of early-stage breast cancer.
    Yardley D; Burris H; Peacock N; Raefsky E; Melnik M; Inhorn R; Shipley D; Hainsworth J
    Breast Cancer Res Treat; 2010 Sep; 123(2):471-5. PubMed ID: 20658263
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High efficacy of pre-operative trastuzumab combined with paclitaxel following doxorubicin & cyclophosphamide in operable breast cancer.
    Paluch-Shimon S; Wolf I; Goldberg H; Evron E; Papa MZ; Shabtai M; Barsuk D; Yosepovich A; Modiano T; Catane R; Kaufman B
    Acta Oncol; 2008; 47(8):1564-9. PubMed ID: 18607846
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Independent adjudication of symptomatic heart failure with the use of doxorubicin and cyclophosphamide followed by trastuzumab adjuvant therapy: a combined review of cardiac data from the National Surgical Adjuvant breast and Bowel Project B-31 and the North Central Cancer Treatment Group N9831 clinical trials.
    Russell SD; Blackwell KL; Lawrence J; Pippen JE; Roe MT; Wood F; Paton V; Holmgren E; Mahaffey KW
    J Clin Oncol; 2010 Jul; 28(21):3416-21. PubMed ID: 20530275
    [TBL] [Abstract][Full Text] [Related]  

  • 17. From the molecule to the clinic--inhibiting HER2 to treat breast cancer.
    Eisenhauer EA
    N Engl J Med; 2001 Mar; 344(11):841-2. PubMed ID: 11248162
    [No Abstract]   [Full Text] [Related]  

  • 18. Sequential adjuvant therapy with doxorubicin/paclitaxel/cyclophosphamide for resectable breast cancer involving four or more axillary nodes.
    Hudis CA; Seidman AD; Baselga J; Raptis G; Lebwohl D; Gilewski T; Currie V; Moynahan ME; Sklarin N; Fennelly D
    Semin Oncol; 1995 Dec; 22(6 Suppl 15):18-23. PubMed ID: 8643965
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiotoxicity concerns prompt data review in breast cancer trial.
    Friedrich MJ
    J Natl Cancer Inst; 2002 May; 94(9):650-1. PubMed ID: 11983752
    [No Abstract]   [Full Text] [Related]  

  • 20. Trastuzumab plus chemotherapy improves survival in early-stage HER2-positive breast cancer patients.
    Oncology (Williston Park); 2005 Jun; 19(7):851, 862. PubMed ID: 16053034
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.